Hospital
Glendive Medical Center, INC
Glendive Medical Center, INC was paid $593K by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoGLENDIVE MEDICAL CENTER, INC
GLENDIVE, MT 59330
GLENDIVE, MT 59330
33aNPI1376552893assigned 08/05/2006
33bProvider typeCritical Access Hospital
28Total paid$593K
24GClaims98,645
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Montana
Rank by total paid#9 of 25
Median peer was paid$185K
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,022 | $46K | |
| 2019 | 11,976 | $64K | |
| 2020 | 11,271 | $40K | |
| 2021 | 16,072 | $79K | |
| 2022 | 18,407 | $126K | |
| 2023 | 17,328 | $136K | |
| 2024incomplete | 12,569 | $102K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 4,888 | 4,002 | $131K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14% | 949 | 908 | $84K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 4,915 | 3,355 | $76K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.3% | 536 | 496 | $31K |
| 80053 | Comprehensive metabolic panel | 3.8% | 9,520 | 7,383 | $23K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.8% | 4,293 | 1,178 | $22K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 1,382 | 1,204 | $19K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 580 | 428 | $18K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 9,453 | 7,109 | $16K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 1,085 | 739 | $14K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 1,599 | 1,055 | $12K |
| 71046 | Radiologic examination, chest; 2 views | 1.9% | 1,204 | 867 | $11K |
85 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 1,735 | $10K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.5% | 308 | $9K |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 12,480 | $8K |
| 87070 | 1.3% | 457 | $7K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 2,329 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 1,015 | $7K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 2,243 | $6K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 65 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 486 | $5K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 471 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,085 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,674 | $4K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 34 | $3K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,827 | $3K |
| 83690 | <1% | 701 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,367 | $3K |
| 83540 | <1% | 478 | $3K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 242 | $3K |
| 81001 | <1% | 1,656 | $3K | |
| 80061 | Lipid panel | <1% | 1,165 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,401 | $2K |
| 82150 | <1% | 246 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,228 | $2K |
| 83735 | <1% | 974 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 173 | $2K |
| 83605 | <1% | 1,091 | $2K | |
| 81003 | <1% | 2,225 | $2K | |
| 85651 | <1% | 272 | $1K | |
| 86140 | <1% | 261 | $1K | |
| 85027 | <1% | 1,960 | $1K | |
| 85610 | <1% | 1,077 | $1K | |
| 97161 | <1% | 148 | $1K | |
| 82728 | <1% | 185 | $1K | |
| 87186 | <1% | 432 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,707 | $974.94 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 311 | $907.70 |
| 87077 | <1% | 495 | $843.36 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 193 | $837.00 |
| 84703 | <1% | 195 | $823.45 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 699 | $679.13 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,413 | $633.92 |
| 80306 | <1% | 253 | $627.66 | |
| 81025 | <1% | 248 | $610.20 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 179 | $527.33 |
| 83550 | <1% | 95 | $513.90 | |
| 84439 | <1% | 30 | $511.20 | |
| 82607 | <1% | 168 | $494.10 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 754 | $437.43 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 163 | $349.48 |
| 84484 | <1% | 869 | $343.93 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 369 | $310.23 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 370 | $306.13 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $270.90 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 36 | $270.00 |
| 82077 | <1% | 126 | $265.50 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 307 | $243.72 |
| 73610 | <1% | 46 | $226.80 | |
| J2704 | Injection, propofol, 10 mg | <1% | 143 | $187.65 |
| 85730 | <1% | 59 | $184.19 | |
| 82746 | <1% | 73 | $172.80 | |
| 99000 | <1% | 705 | $171.90 | |
| 85379 | <1% | 190 | $171.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 140 | $103.50 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 47 | $44.40 |
| 82962 | <1% | 18 | $37.80 | |
| 85652 | <1% | 18 | $27.90 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 526 | $21.49 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 123 | $17.08 |
| G0378 | Hospital observation service, per hour | 0% | 17 | $0.00 |
| 82550 | 0% | 34 | $0.00 | |
| 96376 | 0% | 14 | $0.00 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 143 | $0.00 |
| 86850 | 0% | 30 | $0.00 | |
| 82553 | 0% | 30 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 69 | $0.00 |
| 83874 | 0% | 30 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 13 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 56 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 13 | $0.00 |
| 76377 | 0% | 19 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 19 | $0.00 |
| 86900 | 0% | 46 | $0.00 | |
| 82570 | 0% | 13 | $0.00 | |
| 73562 | 0% | 80 | $0.00 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROBINSON, WILLIAM (VICE-PRESIDENT OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Glendive Medical Center, INC | Glendive, MT | $171K |
| Glendive Medical Center, INC | Glendive, MT | $17K |
| Glendive Medical Center, INC | Glendive, MT | $2K |
| Glendive Medical Center, INC | Glendive, MT | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.